LLY241018C890000
- 43.45
- -1.25-2.80%
Eli Lilly and Co Newsroom
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Leerink Partners Initiates Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $990
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,158
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Eli Lilly Analyst Ratings
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,033
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Eli Lilly Analyst Ratings
Deutsche Bank Reiterates Buy on Eli Lilly, Maintains $1025 Price Target
Guggenheim Adjusts Eli Lilly and Company Price Target to $884 From $1,030
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,025
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,150
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025